Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies

ABSTRACT A small pool of infected cells persists in HIV-infected individuals receiving antiretroviral therapy (ART). Here, we developed ultrasensitive assays to precisely measure the frequency of cells harboring total HIV DNA, integrated HIV DNA, and two long terminal repeat (2-LTR) circles. These assays are performed on cell lysates, which circumvents the labor-intensive step of DNA extraction, and rely on the coquantification of each HIV molecular form together with CD3 gene sequences to precisely measure cell input. Using primary isolates from HIV subtypes A, B, C, D, and CRF01_A/E, we demonstrate that these assays can efficiently quantify low target copy numbers from diverse HIV subtypes. We further used these assays to measure total HIV DNA, integrated HIV DNA, and 2-LTR circles in CD4+ T cells from HIV-infected subjects infected with subtype B. All samples obtained from ART-naive subjects were positive for the three HIV molecular forms (n = 15). Total HIV DNA, integrated HIV DNA, and 2-LTR circles were detected in, respectively, 100%, 94%, and 77% of the samples from individuals in which HIV was suppressed by ART. Higher levels of total HIV DNA and 2-LTR circles were detected in untreated subjects than individuals on ART (P = 0.0003 and P = 0.0004, respectively), while the frequency of CD4+ T cells harboring integrated HIV DNA did not differ between the two groups. These results demonstrate that these novel assays have the ability to quantify very low levels of HIV DNA of multiple HIV subtypes without the need for nucleic acid extraction, making them well suited for the monitoring of viral persistence in large populations of HIV-infected individuals. IMPORTANCE Since the discovery of viral reservoirs in HIV-infected subjects receiving suppressive ART, measuring the degree of viral persistence has been one of the greatest challenges in the field of HIV research. Here, we report the development and validation of ultrasensitive assays to measure HIV persistence in HIV-infected individuals from multiple geographical regions. These assays are relatively inexpensive, do not require DNA extraction, and can be completed in a single day. Therefore, they are perfectly adapted to monitor HIV persistence in large cohorts of HIV-infected individuals and, given their sensitivity, can be used to monitor the efficacy of therapeutic strategies aimed at interfering with HIV persistence after prolonged ART.

[1]  R. Siliciano,et al.  Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient , 2013, PLoS pathogens.

[2]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[3]  Y. Pommier,et al.  Azido-Containing Diketo Acid Derivatives Inhibit Human Immunodeficiency Virus Type 1 Integrase In Vivo and Influence the Frequency of Deletions at Two-Long-Terminal-Repeat-Circle Junctions , 2004, Journal of Virology.

[4]  R. Siliciano,et al.  Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. , 2005, Methods in molecular biology.

[5]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[6]  C. Rouzioux,et al.  A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir , 2010, Journal of medical virology.

[7]  H. Fleury,et al.  Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA , 2000, AIDS.

[8]  J. Farrar,et al.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. , 2011, AIDS.

[9]  C. Rouzioux,et al.  The measurement of HIV-1 viral load in resource-limited settings: how and where? , 2007, Clinical laboratory.

[10]  Namshin Kim,et al.  Human Immunodeficiency Virus Integration Efficiency and Site Selection in Quiescent CD4+ T Cells , 2009, Journal of Virology.

[11]  B. Levine,et al.  A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. , 2008, Virology.

[12]  C. Rouzioux,et al.  LTR Real-Time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants Born to Seropositive Mothers Treated in HAART Area ( ANRS CO 01 ) , 2008 .

[13]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[14]  V. Natarajan,et al.  Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cells. , 2013, Journal of virological methods.

[15]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[16]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[17]  A. Fauci,et al.  Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. , 1989, Journal of immunology.

[18]  D. Cooper,et al.  HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy , 2014, Journal of Virology.

[19]  U. O’Doherty,et al.  Quantitation of integrated proviral DNA in viral reservoirs , 2013, Current opinion in HIV and AIDS.

[20]  Rebecca Hoh,et al.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. , 2013, The Journal of infectious diseases.

[21]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[22]  F. Buonaguro,et al.  Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.

[23]  S. Lewin,et al.  HIV cure and eradication: how will we get from the laboratory to effective clinical trials? , 2011, AIDS.

[24]  P. Sonigo,et al.  Evidence for Gene Expression by Unintegrated Human Immunodeficiency Virus Type 1 DNA Species , 2004, Journal of Virology.

[25]  Mario Roederer,et al.  T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.

[26]  A. Bhandoola,et al.  Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. , 2011, Virology.

[27]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.

[28]  F. Bushman Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. , 2003, AIDS.

[29]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[30]  C. B. Hare,et al.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.

[31]  P. Massip,et al.  Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART , 2005, AIDS.

[32]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[33]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[34]  Avettand‐Fènoël Véronique,et al.  LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .

[35]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[36]  R. Siliciano,et al.  Experimental approaches to the study of HIV-1 latency , 2007, Nature Reviews Microbiology.

[37]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[38]  T. Calvez,et al.  Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection , 2003, AIDS.

[39]  P. Sonigo,et al.  Analysis of Early Human Immunodeficiency Virus Type 1 DNA Synthesis by Use of a New Sensitive Assay for Quantifying Integrated Provirus , 2003, Journal of Virology.

[40]  J. Mills,et al.  Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes , 1996, Journal of virology.

[41]  R. Paredes,et al.  Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART , 2011, PLoS pathogens.

[42]  S. Lewin,et al.  Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. , 2010, The Journal of infectious diseases.

[43]  L. Montaner,et al.  Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials , 2012, AIDS.

[44]  T. Perneger,et al.  Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions , 2004, AIDS.

[45]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[46]  M. Lederman,et al.  Interleukin-7 promotes HIV persistence during antiretroviral therapy. , 2013, Blood.

[47]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[48]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.